Downloadable slideset covering key HIV studies presented at IDWeek, Comorbidities Workshop, and HIV Glasgow 2018, reported by Clinical Care Options
Study 1878: Suppression maintained through Week 48 after switch to BIC/FTC/TAF with M184V/I presented at Glasgow 2018 reported by Clinical Care Options
Phase III NAMSAL ANRS 12313: Week 48 results from Glasgow 2018 on DTG vs EFV 400 mg + 3TC/TDF in ART-naive adults, as reported by Clinical Care Options (CCO).
Subgroup analyses of safety and efficacy at Week 48 in phase III GEMINI-1 and -2 presented at Glasgow 2018 as reported by Clinical Care Options (CCO).
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.